Elisa H Ignatius1, Susan Swindells2. 1. Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. 2. University of Nebraska Medical Center, Omaha, NE, 68198-8106, USA. sswindells@unmc.edu.
Abstract
PURPOSE OF REVIEW: Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV. RECENT FINDINGS: After many years without new agents, there is now active testing of many novel drugs to treat TB, both for latent infection and active disease. Though not all studies have included patients with HIV, many have, and there are ongoing trials to address key implementation challenges such as potent drug-drug interactions with ART. The goal of short-course regimens for TB is to enhance treatment completion without compromising efficacy. Particularly among patients with HIV, studying these shortened regimens and integrating them into clinical care are of urgent importance. There are now multiple short-course regimens for latent infection and active disease that are safe and effective among patients with HIV.
PURPOSE OF REVIEW: Despite broad uptake of antiretroviral therapy (ART), tuberculosis (TB) incidence and mortality among people with HIV remain unacceptably high. Short-course regimens for TB, incorporating both novel and established drugs, offer the potential to enhance adherence and completion rates, thereby reducing the global TB burden. This review will outline short-course regimens for TB among patients with HIV. RECENT FINDINGS: After many years without new agents, there is now active testing of many novel drugs to treat TB, both for latent infection and active disease. Though not all studies have included patients with HIV, many have, and there are ongoing trials to address key implementation challenges such as potent drug-drug interactions with ART. The goal of short-course regimens for TB is to enhance treatment completion without compromising efficacy. Particularly among patients with HIV, studying these shortened regimens and integrating them into clinical care are of urgent importance. There are now multiple short-course regimens for latent infection and active disease that are safe and effective among patients with HIV.
Authors: Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Betina Durovni; Valeria Saraceni; Lawrence H Moulton; Antonio G Pacheco; Solange C Cavalcante; Bonnie S King; Silvia Cohn; Anne Efron; Richard E Chaisson; Jonathan E Golub Journal: Lancet Infect Dis Date: 2013-08-16 Impact factor: 25.071
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: N Ndjeka; F Conradie; K Schnippel; J Hughes; N Bantubani; H Ferreira; G Maartens; D Mametja; G Meintjes; X Padanilam; E Variava; A Pym; Y Pillay Journal: Int J Tuberc Lung Dis Date: 2015-08 Impact factor: 2.373
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: Kelly E Dooley; Radojkam Savic; Akshay Gupte; Mark A Marzinke; Nan Zhang; Vinodh A Edward; Lisa Wolf; Modulakgotla Sebe; Morongwe Likoti; Mark J Fyvie; Innocent Shibambo; Trevor Beattie; Richard E Chaisson; Gavin J Churchyard Journal: Lancet HIV Date: 2020-03-30 Impact factor: 12.767
Authors: Marc Weiner; Eric F Egelund; Melissa Engle; Melissa Kiser; Thomas J Prihoda; Jonathan A L Gelfond; William Mac Kenzie; Charles A Peloquin Journal: J Antimicrob Chemother Date: 2013-12-15 Impact factor: 5.790